Gilead Invests Further in Arcellx, Extends Collaboration
By Colin Kellaher
Gilead Sciences is investing another $200 million in clinical-stage biotechnology company Arcellx as part of an expansion of the duo's collaboration to include lymphomas.
The companies on Wednesday said Gilead's Kite unit has exercised its option to negotiate a license for Arcellx's ARC-SparX program, ACLX-001, in multiple myeloma, and that they are expanding the scope of the collaboration launched late last year for Arcellx's CART-ddBCMA to include lymphomas.
Foster City, Calif., biopharmaceutical company Gilead, which last year made an initial equity investment of $100 million in Arcellx, will buy another 3.24 million share at $61.68 apiece, a 30% premium to Tuesday's closing price of $47.47 for the Gaithersburg, Md., company.
Arcellx said the investment, which will boost Gilead's stake to about 13%, will extend its cash runway into 2027.
Arcellx also will receive an upfront cash payment of $85 million at closing and will be eligible for potential milestone payments, the companies said.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 15, 2023 06:43 ET (11:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks